Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 14, 2022; 28(26): 3047-3062
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3047
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3047
Table 1 In vitro hepatoprotective effects of baicalin on different cell lines
Disease/type of study | Cell line | Dose | Mechanism/target pathways | Ref. |
Palmitic acid-induced fatty liver | AML-12 hepatocytes | 6.25-25 μM | ER stress↓; TXNIP/NLRP-3 pathway↓ | [50] |
Hypoxic liver injury | L02 human hepatocytes | 100 μmol/L | Caspase-3, caspase-9, and Bax↓ | [58] |
Acetaldehyde induced EMT | HepG2 cells | 20-100 mmol/L | TGF-β/Smad pathway↓ | [59] |
ns-PEF induced liver injury | L02 hepatocytes | 60 μM | MTP stabilization, ROS↓ | [60] |
Hemin-nitrite-H2O2 induced liver injury | HepG2 cells | 5 μM and 25 μM | Lipid peroxidation↓; GSH depletion↓ | [61] |
PDGF-BB induced fibrosis | HSCT6 hepatocytes | 150 μM | miR-3595↓; ACSL-4↑ | [69] |
BDL-induced fibrosis | HSCs | 67.5-270 μM | Wnt pathway↓; PPAR-γ↓ | [70] |
LPS-induced hepatitis | L20, THLE cell lines | 25-100 μM | TUG-1↑; p38-MAPK↓; JNK pathway↓ | [82] |
Viral hepatitis | HuH7, HepG2 cells | 75 μg/mL | NF-κB pathway↓ | [83] |
pHBV1.2HepG2 cells | 10 μM | HNF-4α/HNF-1α↓ | [84] | |
HepG2.2.15 cells | 10 μg/kg | HBsAg, HBeAg↓ | [85] | |
PBMCs | 50-200 mg/mL | Mitochondrial pathway↑; Caspase 3↑ | [87] | |
HCC | HepG2-HCC | 100 μmol/L | ER-mediated TF-6↑; S-2P protein↑ | [94] |
SMMC7721-HCC cells | 160 μM | CD47↓ | [95] | |
SMMC7721, HepG2-HCC cells | 40 μM | STAT3, IFN-γ↓; Block PDL-1/PD-1 pathway | [96,97] |
- Citation: Ganguly R, Gupta A, Pandey AK. Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: A review. World J Gastroenterol 2022; 28(26): 3047-3062
- URL: https://www.wjgnet.com/1007-9327/full/v28/i26/3047.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i26.3047